Thus, both the NCCN and European LeukemiaNet guidelines now recommend testing for FLT3-ITD at diagnosis to guide post-remission therapeutic selection after induction chemotherapy in patients with cytogenetically normal (CN) AML [5]–[8], [10]–[18]. This evidence concerns the gene FLT3 and acute myeloid leukemia.